Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation
British Journal of Pharmacology · 2024-11 · 181 (22) · 4430-4449
DOI: 10.1111/bph.17325 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 24.09.2024. Verfasst von Aida Mohammadkhani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Hotchkiss Brain Institute, The University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Orexins, Motivation, Hypothalamus. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Hunter Medical Research Institute, NIDA NIH HHS.
Abstract (Originalsprache)
The orexin (also known as hypocretin) system, consisting of neuropeptides orexin‐A and orexin‐B, was discovered over 25 years ago and was immediately identified as a central regulator of sleep and wakefulness. These peptides interact with two G‐protein coupled receptors, orexin 1 (OX 1 ) and orexin 2 (OX 2 ) receptors which are capable of coupling to all heterotrimeric G‐protein subfamilies, but primarily transduce increases in calcium signalling. Orexin neurons are regulated by a variety of transmitter systems and environmental stimuli that signal reward availability, including food and drug related cues. Orexin neurons are also activated by anticipation, stress, cues predicting motivationally relevant information, including those predicting drugs of abuse, and engage neuromodulatory systems, including dopamine neurons of the ventral tegmental area (VTA) to respond to these signals. As such, orexin neurons have been characterized as motivational activators that coordinate a range of functions, including feeding and arousal, that allow the individual to respond to motivationally relevant information, critical for survival. This review focuses on the role of orexins in appetitive motivation and highlights a role for these neuropeptides in pathologies characterized by inappropriately high levels of motivated arousal (overeating, anxiety and substance use disorders) versus those in which motivation is impaired (depression).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Hotchkiss Brain Institute, The University of Calgary, Calgary, Alberta, Canada.
- School of Biomedical Sciences and Pharmacy, University of Newcastle, University Drive, Callaghan, New South Wales, Australia.
- The Hunter Medical Research, New Lambton Heights, New South Wales, Australia.
- Department of Psychiatry and Brain Health Institute, Robert Wood Johnson Medical School, Rutgers University, Piscataway, New Jersey, USA.
Förderung
- NIEHS NIH HHS
- Hunter Medical Research Institute
- NIDA NIH HHS
- New Jersey Health Foundation
- National Heart Brain and Lung Institute
- Canada Research Chair
- NHLBI NIH HHS
- NSERC Discovery
Zitieren
APA
Mohammadkhani, A., Mitchell, C., James, M. H., Borgland, S. L., & Dayas, C. V. (2024). Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation. British Journal of Pharmacology, 181(22), 4430-4449. https://doi.org/10.1111/bph.17325
Vancouver
Mohammadkhani A, Mitchell C, James MH, Borgland SL, Dayas CV. Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation. British Journal of Pharmacology. 2024;181(22):4430-4449. doi:10.1111/bph.17325
BibTeX
@article{Mohammadkhani2024,
author = {Mohammadkhani, Aida and Mitchell, Caitlin and James, Morgan H and Borgland, Stephanie L and Dayas, Christopher V},
title = {Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {22},
pages = {4430--4449},
doi = {10.1111/bph.17325}
}
EUVIMED